Enhancing the affinity of novel GLS1 allosteric inhibitors by targeting key residue Lys320

Future Med Chem. 2023 Aug;15(15):1393-1414. doi: 10.4155/fmc-2023-0114. Epub 2023 Aug 23.

Abstract

Aim: A series of novel GLS1 irreversible allosteric inhibitors targeting Lys320 might have robust enzyme inhibitory activity and potent antitumor activity. Materials & methods: Novel GLS1 allosteric inhibitors targeting Lys320 were synthesized and their anticancer activity was assessed. Moreover, GLS1 protein was used as a model system to analyze the reactivity of these electrophilic groups in GLS1 irreversible allosteric inhibitors with other amino acids, including tyrosine, histidine, serine and threonine, using biochemical and biophysical assays. Results: AC16 exhibited robust GLS1 inhibitory activity, antiproliferative effect in vitro, good plasma stability and potential covalent addition with GLS1 K320. Conclusion: This study opens a novel avenue for the design of robust irreversible GLS1 inhibitors targeting the allosteric site K320.

Keywords: GLS1; allosteric; glutamine metabolism; irreversible; lysine.